Moberg Pharma´s Interim report January - September 2022
PROGRESS IN THE REGISTRATION PROCESS AND LAUNCH PREPERATIONSNINE-MONTH PERIOD (JAN-SEP 2022) · EBITDA SEK -13.7 million (-12.9) * · Operating profit (EBIT) -15.6 million (-14.8) * · Profit after tax SEK -12.6 million (-12.2) * · Total profit SEK -12.6 million (11.4)** · Diluted earnings per share SEK -0.18 (0.26)** · Cash and cash equivalents amounted to SEK 142.5 million (111.4) THIRD QUARTER (JUL-SEP 2022) · EBITDA SEK -4.6 million (-4.0) * · Operating profit (EBIT) SEK -5.3 million (-4.7) * · Profit after tax SEK -4.3 million (-3.9) * · Total profit